SOURCE: Premier Biomedical, Inc.
EL PASO, TX--(Marketwired - Feb 11, 2014) - Premier Biomedical, Inc. (OTCQB: BIEI) (OTCBB: BIEI) today announced that President and Chief Executive Officer, William A. Hartman, was recently interviewed for a second time in 16 months by CEO/CFO Magazine, an independent investment publication which conducts interviews with company CEOs. The latest William Hartman interview appears in the publication's Biotechnology and Pharmaceuticals Report available by calling (570) 851-1745 or via CEO/CFO Magazine Online (http://www.ceocfointerviews.com). (The original interview was in the October, 2012 edition.)
In the interview, Mr. Hartman stated, "Premier Biomedical's revolutionary approach to medical treatment research and development employs the Felder Doctrine™, developed by company co-founder Dr. Mitchell Felder, whereby Premier Biomedical physically removes the pathophysiologic basis of a disease by processing body fluids -- blood for blood-borne diseases and cerebral spinal fluid for neurologic-based diseases. Premier Biomedical's therapeutic medication for breast cancer, outperformed chemotherapy with a higher survival rate among mice receiving Premier Biomedical's treatment vs. mice treated with traditional chemotherapy. A confirmatory study further verified that Premier Biomedical's breast cancer therapeutic medication was demonstrated to prevent metastasis -- the leading cause of death among humans with breast cancer. Moreover, a subset of the mice successfully healed of pre-existing breast cancer by Premier Biomedical's cancer medication demonstrated an immunity to subsequent attempts to re-inject breast cancer. This implies a successful manipulation of the immune system to resist breast cancer that is worthy of further testing to verify this potential breakthrough finding.
Mr. Hartman also spoke about Premier Biomedical's developing relationships with college and professional sports organizations in the pursuit of developing an objective and accurate test measurement, and cure, for Traumatic Brain Injury in conjunction with Premier's R&D co-partners, the University of Texas at El Paso (UTEP) and the United States Department of Defense (DOD). He noted, "Through the scientific progress being made by Premier's R&D consortium, the company's goal remains to complete research and development and bring to market potential medications and procedures for a number of targeted diseases that heretofore had been considered incurable."
Commenting on the interview with CEO/CFO Magazine, Mr. Hartman stated, "I welcomed the open nature of the CEO/CFO interview and the opportunity they afforded us to describe in our own words the major healthcare paradigm-changing achievements we have made and continue to make at an ever-increasing rate at Premier Biomedical."
For a copy of the Healthcare issue or for information on subscribing to CEO CFO Magazine, call (570) 851-1745 or visit CEO CFO Magazine Online (http://www.ceocfointerviews.com).
About Premier Biomedical, Inc.
Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for humans, in collaboration with the University of Texas at El Paso and the US Department of Defense, specifically targeting the treatment of Alzheimer's Disease, Fibromyalgia, Multiple Sclerosis, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis (ALS/Lou Gehrig's Disease), Blood Sepsis and Viremia, and Cancer. Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis. Founded in 2010, Premier is headquartered in El Paso, Texas, with offices in Pennsylvania. The Company's common stock trades on the fully reporting Over-The-Counter Bulletin Board under the ticker symbol "BIEI." http://www.premierbiomedicalinc.com/
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates and assumptions made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.